Find clinical trials for Acute Myeloid Leukemia (AML) in Durham, NC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Durham, NC, USA:
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Durham, North Carolina, United States and 33 other locations
CLN-049-001 is a Phase 1/2, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid...
Phase 1, Phase 2
Durham, North Carolina, United States and 16 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...
Phase 3
Chapel Hill, North Carolina, United States and 23 other locations
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (...
Phase 1
Chapel Hill, North Carolina, United States of America and 8 other locations
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...
Phase 3
Durham, North Carolina, United States and 133 other locations
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...
Phase 1
Durham, North Carolina, United States and 43 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Durham, North Carolina, United States and 43 other locations
pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 and spliceosome mutated Relapsed or Refractory Acute...
Phase 1
Chapel Hill, North Carolina, United States and 22 other locations
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain ...
Phase 3
Chapel Hill, North Carolina, United States and 172 other locations
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...
Phase 1
Chapel Hill, North Carolina, United States of America and 36 other locations
Clinical trials
Research sites
Resources
Legal